FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome
14 févr. 2023 08h30 HE
|
Albireo Pharma, Inc.
Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 déc. 2022 16h30 HE
|
Albireo Pharma, Inc.
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
19 déc. 2022 08h30 HE
|
Albireo Pharma, Inc.
- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low...
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06 déc. 2022 16h30 HE
|
Albireo Pharma, Inc.
BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors
06 déc. 2022 08h30 HE
|
Albireo Pharma, Inc.
– Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise – Dr. Paul Streck, former Chief...
Inscription sur la liste des médicaments remboursables aux assurés sociaux de Bylvay® (odevixibat) pour les patients atteints de PFIC 1 & 2 (à l’exception du sous- type BSEP3 de la PFIC 2) chez les patients âgés de 6 mois et plus
30 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, 30 nov. 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq : ALBO), une société spécialisée dans les maladies rares qui développe de nouveaux modulateurs d'acides biliaires pour traiter...
Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2
30 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo to Participate in Jefferies London Healthcare Conference
09 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today...
Albireo Reports Q3 2022 Financial Results and Business Update
08 nov. 2022 16h01 HE
|
Albireo Pharma, Inc.
Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD...
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types
07 nov. 2022 08h30 HE
|
Albireo Pharma, Inc.
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and...